<?xml version="1.0" encoding="UTF-8" ?>
<pdf>
    <fonts>
        <font id="simsun"     embedded="true" name="simsun"     ttf_path="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/simsun.ttc,1"/>
        <font id="fzlthjw"    embedded="true" name="fzlthjw"    ttf_path="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/fzlthjw.ttf"/>
        <font id="fzltchjw"   embedded="true" name="fzltchjw"   ttf_path="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/fzltchjw.ttf"/>
        <font id="fzltxh_gbk" embedded="true" name="fzltxh_gbk" ttf_path="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/fzltxh_gbk.ttf"/>
    </fonts>






    <data>
        <parameter id="diseaseName" value="（肺癌）"/>
        <parameter id="letterContent" value="">
<![CDATA[您好！<br/>
<br/>
感谢您选择我们为您提供的肿瘤精准医疗检测服务。我们本着科学、严谨、求实的精神，采用最先进的基因检测技术，以当前国际权威的研究成果和临床指南为理论依据，严格按照参考文献中报道的基因与疾病的关联强度，客观准确地为您提供这份个性化的基因检测报告。<br/>
<br/>
我们每个人都有自己独特的基因，每一位肿瘤患者所携带的致病基因也不尽相同，同样分型分期的肿瘤，使用同一药物的治疗效果也可能存在巨大差异。因此，传统的组织病理诊断已不能满足目前临床肿瘤诊疗的客观需求。随着医学技术的迅速发展和对肿瘤研究的不断深入，肿瘤诊疗已进入“精准医疗时代”。通过检测受检者血液的 cfDNA 或肿瘤组织的基因组，寻找到肿瘤发病的原因和治疗的靶点，从对“症”治疗向对“因”治疗转变，同一肿瘤可能因不同的基因变异而选用不同的治疗药物，不同的肿瘤也可能因有相同的基因变异而使用同一治疗药物，从而实现真正意义上的“同病异治”和“异病同治”。<br/>
<br/>
我们为您提供的肿瘤精准医疗检测服务涵盖了肿瘤的遗传早筛，精准用药及实时监控三个部分，可实现肿瘤精准医疗的全方位、全进程检测，最大限度的满足不同阶段肿瘤患者的需求。每位受检者均可根据自身情况和需求选择相应的检测产品。<br/>
<br/>
此服务本质上属于研究性检测，是为了更好地协助您了解自身罹患肿瘤的风险及可能的致病基因，并为临床检测提供 DNA 水平的分析参考，而不具有直接诊断和治疗的目的，具体干预措施请以临床医生意见为准。<br/>
<br/>
基因信息属于个人隐私，我们郑重承诺将妥善保管您的相关数据，未经您本人授权不会用于其他目的。若因您个人原因发生信息外泄，其后果将由您本人承担。<br/>
<br/>
我们恭祝您身体健康、工作顺利、家庭幸福！]]>
        </parameter>
        <parameter id="name"   value="王辉"/>
        <parameter id="gender" value="女"/>
        <parameter id="age" value="55"/>
        <parameter id="diagnoses" value="原发性肝细胞癌，中分化"/>
        <parameter id="sampleNumb" value="1234567890123456"/>
        <parameter id="sampleType" value="肿瘤组织"/>
        <parameter id="collectDate" value="2017 / 05 / 01"/>
        <parameter id="receiveDate" value="2017 / 05 / 10"/>
        <parameter id="admissionNumb" value="20170510—12342314"/>
        <parameter id="familyHistory" value="">
            <![CDATA[其肿瘤家族史未知。<br/>]]>
        </parameter>
        <parameter id="checkContent" value="">
            <![CDATA[· 检测内容:肿瘤靶向化疗用药标准检测<br/>
· 检测方法:高通量测序<br/>
· 主要设备:<br/>
· 数据分析软件及库:序列比对软件 BWA, 检测突变软件 Freebayes; 临床数据库: PharmGKB, HGMD, ClinVar, COSMIC, SNPedia, 1000genomes, dbSNP<br/>
]]>
        </parameter>
        <parameter id="geneMutationSite" value="">
<![CDATA[<style italic='true'>EGFR</style> p.L858R]]>
        </parameter>
        <parameter id="allergicMedicine" value="">
<![CDATA[吉非替尼、厄洛替尼、阿法替尼、埃克替尼]]>
        </parameter>
        <parameter id="geneAnalysis" value="">
<![CDATA[
大量研究资料表明 <style italic='true'>EGFR</style> 基因突变主要集中在酪氨酸激酶区（外显子 18-21），其中 19 外显子多为框内缺失（746-753）突变，约占所有突变的 45%；21 外显子多为替代突变（主要是 L858R），约占所有突变的 40%。<style italic='true'>EGFR</style> 基因编码区外显子 18、19 和 21 的基因突变是患者对临床 EGFR-TKI 靶向治疗药物有效的必要前提。研究发现，非小细胞肺癌细胞中 <style italic='true'>EGFR</style> 酪氨酸激酶基因编码区外显子 18、19 或 21 突变的患者，酪氨酸激酶抑制剂（TKIs）如易瑞沙（吉非替尼）、特罗凯（厄洛替尼）治疗的有效性显著增强。美国国立综合癌症网络（NCCN）2015 年版临床指南和美国临床肿瘤学会（ASCO）IV 期非小细胞肺癌诊疗指南 2009 年更新版中已明确指出，肿瘤 <style italic='true'>EGFR</style> 突变的前提下，推荐吉非替尼和厄洛替尼为非小细胞肺癌一线治疗药物。
<br/><br/>在患者肿瘤基因组中检测出 <style italic='true'>EGFR</style> 的 L858R 突变，提示患者对吉非替尼、厄洛替尼具有较强敏感性，适用于此类药物治疗。
]]>
        </parameter>
        <parameter id="appendixReferences" value="">
<![CDATA[1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
<br/><br/>2. Ascierto P A, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma[J]. Journal of Clinical Oncology, 2013, 31(26): 3205-3211.
<br/><br/>3. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study[J]. Journal of Clinical Oncology, 2012, 30(22): 2718-2724.
<br/><br/>4. Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. The Lancet, 2010, 376(9742): 687-697.
<br/><br/>5. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non–small-cell lung cancer: AVAPERL (MO22089)[J]. Journal of Clinical Oncology, 2013, 31(24): 3004-3011.
<br/><br/>6. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial[J]. The Lancet, 2012, 379(9816): 633-640.
<br/><br/>7. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer[J]. New England Journal of Medicine, 2012, 366(6): 520-529.
<br/><br/>8. Baselga J, Cortés J, Kim S B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. New England Journal of Medicine, 2012, 366(2): 109-119.
<br/><br/>9. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer[J]. Journal of Clinical Oncology, 2009, 27(16): 2630-2637.
<br/><br/>10. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial[J]. The lancet oncology, 2013, 14(1): 29-37.
<br/><br/>11. Berns K, Horlings H M, Hennessy B T, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer[J]. Cancer cell, 2007, 12(4): 395-402.
<br/><br/>12. Blanke C D, Demetri G D, Von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT[J]. Journal of Clinical Oncology, 2008, 26(4): 620-625.
<br/><br/>13. Camidge D R, Bang Y J, Kwak E L, et al. Activity and safety of crizotinib in patients with ALK-positive non- small-cell lung cancer: updated results from a phase 1 study[J]. The lancet oncology, 2012, 13(10): 1011-1019.
<br/><br/>14. Chapman P B, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. New England Journal of Medicine, 2011, 364(26): 2507-2516.
<br/><br/>15. Cizkova M, Dujaric M E, Lehmann-Che J, et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab[J]. British journal of cancer, 2013, 108(9): 1807-1809.
<br/><br/>16. Contreras A, Herrera S, Wang T, et al. Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients[J]. Cancer Research, 2013, 73(24 Supplement): PD1-2-PD1-2.
<br/><br/>17. Corless C L, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib[J]. Journal of clinical oncology, 2005, 23(23): 5357-5364.
<br/><br/>18. Cui C, Mao L, Chi Z, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma[J]. Molecular Therapy, 2013, 21(7): 1456-1463.
<br/><br/>19. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis[J]. The lancet oncology, 2010, 11(8): 753-762.
<br/><br/>20. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group[J]. European Journal of Cancer, 2004, 40(5): 689- 695.
<br/><br/>21. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group[J]. European Journal of Cancer, 2004, 40(5): 689- 695.
<br/><br/>22. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours[J]. European journal of cancer, 2006, 42(8): 1093-1103.
<br/><br/>23. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy[J]. British journal of cancer, 2007, 96(8): 1166-1169.
<br/><br/>24. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer[J]. Journal of Clinical Oncology, 2008, 26(35): 5705-5712.
<br/><br/>25. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factorreceptor and in KRAS are predictive and prognostic indicators in patients with non-smallcell lung cancer treated with chemotherapy alone and in combination with erlotinib. J ClinOncol 2005;23:5900-5909.
<br/><br/>26. Esteva F J, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer[J]. The American journal of pathology, 2010, 177(4): 1647-1656.
<br/><br/>27. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer[J]. Cancer discovery, 2014, 4(6): 662-673.
<br/><br/>28. Fujita T, Doihara H, Kawasaki K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer[J]. British journal of cancer, 2006, 94(2): 247-252.
<br/><br/>29. Gajiwala K S, Wu J C, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients[J]. Proceedings of the National Academy of Sciences, 2009, 106(5): 1542-1547.
<br/><br/>30. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib[J]. Journal of Thoracic Oncology, 2012, 7(10): e23-e24.
<br/><br/>31. Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. New England Journal of Medicine, 2006, 355(26): 2733-2743.
<br/><br/>32. Gianni L, Pienkowski T, Im Y H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. The lancet oncology, 2012, 13(1): 25-32.
<br/><br/>33. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification[J]. Journal of Clinical Oncology, 2011, 29(21): 2904-2909.
<br/><br/>34. Hauschild A, Grob J J, Demidov L V, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial[J]. The Lancet, 2012, 380(9839): 358-365.
<br/><br/>35. Hodi F S, Corless C L, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin[J]. Journal of Clinical Oncology, 2013, 31(26): 3182-3190.
<br/><br/>36. Hyman D M, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. New England Journal of Medicine, 2015, 373(8): 726-736.
<br/><br/>37. Jhawer M, Goel S, Wilson A J, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab[J]. Cancer research, 2008, 68(6): 1953- 1961.
<br/><br/>38. Johnson D B, Flaherty K T, Weber J S, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor[J]. Journal of Clinical Oncology, 2014, 32(33): 3697-3704.
<br/><br/>39. Kim K B, Kefford R, Pavlick A C, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor[J]. Journal of Clinical Oncology, 2013, 31(4): 482-489.
<br/><br/>40. Kindler H L, Friberg G, Singh D A, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer[J]. Journal of Clinical Oncology, 2005, 23(31): 8033-8040.
<br/><br/>41. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours[J]. Histopathology, 2008, 53(3): 245-266.
<br/><br/>42. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer[J]. Journal of Clinical Oncology, 2009, 27(35): 5924-5930.
<br/><br/>43. Lièvre A, Bachet J B, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab[J]. Journal of Clinical Oncology, 2008, 26(3): 374-379.
<br/><br/>44. Lievre A, Bachet J B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer[J]. Cancer research, 2006, 66(8): 3992-3995.
<br/><br/>45. Lin N U, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer[J]. Clinical Cancer Research, 2009, 15(4): 1452-1459.
<br/><br/>46. Linardou H, Dahabreh I J, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer[J]. The lancet oncology, 2008, 9(10): 962-972.
<br/><br/>47. Long G V, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial[J]. The Lancet, 2015, 386(9992): 444-451.
<br/><br/>48. Long G V, Trefzer U, Davies M A, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial[J]. The lancet oncology, 2012, 13(11): 1087-1095.
<br/><br/>49. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR[J]. New England Journal of Medicine, 2010, 362(25): 2380-2388.
<br/><br/>50. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial[J]. The lancet oncology, 2010, 11(9): 845-852.
<br/><br/>51. Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort[J]. Journal of Clinical Oncology, 2015, 33(9): 992-999.
<br/><br/>52. McArthur G A, Chapman P B, Robert C, et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study[J]. The lancet oncology, 2014, 15(3): 323-332.
<br/><br/>53. Miles D W, Chan A, Dirix L Y, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer[J]. Journal of Clinical Oncology, 2010, 28(20): 3239-3247.
<br/><br/>54. Nagata Y, Lan K H, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients[J]. Cancer cell, 2004, 6(2): 117-127.
<br/><br/>55. Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis- mutations in the activation loop of the KIT gene[J]. International journal of clinical oncology, 2009, 14(2): 143- 149.
<br/><br/>56. Ohtsu A, Shah M A, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study[J]. Journal of Clinical Oncology, 2011: JCO. 2011.36. 2236.
<br/><br/>57. Ou S H I, Bang Y J, Camidge D R, et al. Efficacy and safety of crizotinib in patients with advanced ROS1- rearranged non-small cell lung cancer (NSCLC)[C]//ASCO Annual Meeting Proceedings. 2013, 31(15_suppl): 8032.
<br/><br/>58. Ou S H I, Kwak E L, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification[J]. Journal of thoracic oncology, 2011, 6(5): 942-946.
<br/><br/>59. Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676): 1497-1500.
<br/><br/>60. Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in patients with EGFR mutant advanced non- small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther 2012;11:2535-2540.
<br/><br/>61. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
<br/><br/>62. Pao W, Wang T Y, Riely G J, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib[J]. PLoS Med, 2005, 2(1): e17.
<br/><br/>63. Peeters M, Douillard J Y, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab[J]. Journal of Clinical Oncology, 2013, 31(6): 759-765.
<br/><br/>64. Peeters M, Oliner K S, Price T J, et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer[J]. Clinical Cancer Research, 2015, 21(24): 5469-5479.
<br/><br/>65. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis[J]. European Journal of Cancer, 2015, 51(5): 587-594.
<br/><br/>66. Planchard D, Groen HJM, Min Kim T, et al. Interim results of a phase II study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in patients with BRAF V600E mutated metastatic non-small cell lung cancer. J Clin Oncol 2015;33: Abstract 8006.
<br/><br/>67. Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients [abstract]. J Clin Oncol 2013;31(Suppl 15): Abstract 8009.
<br/><br/>68. Razis E, Bobos M, Kotoula V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer[J]. Breast cancer research and treatment, 2011, 128(2): 447-456.
<br/><br/>69. Robert N J, Diéras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer[J]. Journal of Clinical Oncology, 2011, 29(10): 1252-1260.
<br/><br/>70. Robinson S D, O'Shaughnessy J A, Cowey C L, et al. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib[J]. Lung Cancer, 2014, 85(2): 326-330.
<br/><br/>71. Romond E H, Perez E A, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer[J]. New England Journal of Medicine, 2005, 353(16): 1673-1684.
<br/><br/>72. Sandler A, Gray R, Perry M C, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer[J]. New England Journal of Medicine, 2006, 355(24): 2542-2550.
<br/><br/>73. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies[J]. Cancer research, 2009, 69(5): 1851-1857.
<br/><br/>74. Schneider B P, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100[J]. Journal of Clinical Oncology, 2008, 26(28): 4672-4678.
<br/><br/>75. Sequist L V, Martins R G, Spigel D, et al. First-line gefitinib in patients with advanced non–small-cell lung cancer harboring somatic EGFR mutations[J]. Journal of Clinical Oncology, 2008, 26(15): 2442-2449.
<br/><br/>76. Sequist L V, Yang J C H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. Journal of Clinical Oncology, 2013, 31(27): 3327-3334.
<br/><br/>77. Seymour M T, Brown S R, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial[J]. The lancet oncology, 2013, 14(8): 749-759.
<br/><br/>78. Shah M A, Ramanathan R K, Ilson D H, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma[J]. Journal of Clinical Oncology, 2006, 24(33): 5201-5206.
<br/><br/>79. Shaw A T, Kim D W, Mehra R, et al. Ceritinib in ALK-rearranged non–small-cell lung cancer[J]. New England Journal of Medicine, 2014, 370(13): 1189-1197.
<br/><br/>80. Shaw A T, Kim D W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. New England Journal of Medicine, 2013, 368(25): 2385-2394.
<br/><br/>81. Shaw A T, Ou S H I, Bang Y J, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer[J]. New England Journal of Medicine, 2014, 371(21): 1963-1971.
<br/><br/>82. Shaw A T, Yeap B Y, Solomon B J, et al. Effect of crizotinib on overall survival in patients with advanced non- small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis[J]. The lancet oncology, 2011, 12(11): 1004-1012.
<br/><br/>83. Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[J]. The lancet oncology, 2013, 14(10): 953-961.
<br/><br/>84. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. New England Journal of Medicine, 2011, 365(14): 1273-1283.
<br/><br/>85. Sosman J A, Kim K B, Schuchter L, et al. Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib[J]. New England Journal of Medicine, 2012, 366(8): 707-714.
<br/><br/>86. Swain S M, Kim S B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo- controlled, phase 3 study[J]. The lancet oncology, 2013, 14(6): 461-471.
<br/><br/>87. Tebbutt N C, Wilson K, Gebski V J, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study[J]. Journal of Clinical Oncology, 2010, 28(19): 3191-3198.
<br/><br/>88. Van Cutsem E, de Haas S, Kang Y K, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial[J]. Journal of Clinical Oncology, 2012: JCO. 2011.39. 9824.
<br/><br/>89. Van Cutsem E, Vervenne W L, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer[J]. Journal of Clinical Oncology, 2009, 27(13): 2231-2237.
<br/><br/>90. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. New England Journal of Medicine, 2012, 367(19): 1783-1791.
<br/><br/>91. Wu Y L, Zhou C, Hu C P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]. The lancet oncology, 2014, 15(2): 213-222.
<br/><br/>92. Xiao L, Yang S C, Hao J, et al. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis[J]. Cancer letters, 2015, 359(1): 148-154.
<br/><br/>93. Yang J C H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations[J]. Journal of Clinical Oncology, 2013: JCO. 2012.46. 1764.
<br/><br/>94. Zhu C Q, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21[J]. Journal of Clinical Oncology, 2008, 26(26): 4268-4275.
]]>
</parameter>


        <tree_node id="catalog" value="目录" english="" page="" catalog="0 0">
            <tree_node value="一" english="" page="" catalog="1 0">
                <tree_node english="" page="001" value="样本提供者信息" catalog="1 1">
                </tree_node>
            </tree_node>
            <tree_node value="二" english="" page="" catalog="1 0">
                <tree_node english="" page="xxx" value="个人病史及肿瘤家族史调查" catalog="1 1"/>
            </tree_node>
            <tree_node value="三" english="" page="" catalog="1 0">
                <tree_node english="" page="xxx" value="项目内容" catalog="1 1"/>
            </tree_node>
            <tree_node value="四" english="" page="" catalog="2 0">
                <tree_node english="" page="xxx" value="用药提示" catalog="2 0"/>
                <tree_node english="" page="xxx" value="分子靶向用药提示" catalog="2 1"/>
                <tree_node english="" page="xxx" value="靶向药物简述" catalog="2 2"/>
            </tree_node>
            <tree_node value="五" english="" page="" catalog="5 0">
                <tree_node english="" page="xxx" value="本次检测具体位点结果"   catalog="5 1 0"/>
                <tree_node english="" page="xxx" value="本次检测的分子靶向基因" catalog="5 2 0"/>
            </tree_node>
            <tree_node value="六" english="" page="" catalog="6 0">
                <tree_node english="" page="xxx" value="本次检测的基因列表" catalog="6 1"/>
            </tree_node>
            <tree_node value="附录" english="Appendix" page="" catalog="10000 0 0">
                <tree_node english="" page="xxx" value="靶向用药表格说明示例" catalog="10000 1"/>
                <tree_node english="" page="xxx" value="常见癌种中的靶向药物简介，FDA 获批适应症及 NCCN 指导意见" catalog="10000 2"/>
                <tree_node english="" page="xxx" value="参考文献"      catalog="10000 3"/>
            </tree_node>
        </tree_node>







        <repeat id="specificDrugsForSpecificCancer">
            <group id="0" order="0">
                <parameter id="everyDiseaseName" value="1、非小细胞肺癌"/>
                <parameter id="adaptionDiseaseMedicineInfo" value="">
<![CDATA[
<style font='fzltchjw' font_color='#000000' font_size='13'>获批适应症：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Erlotinib</style><br/>
可用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移的非小细胞肺癌。NCCN2016 年版临床指南明确指出，肿瘤 EGFR 突变的前提下，推荐厄洛替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Gefitinib</style><br/>
可用于非小细胞肺癌的二线治疗。NCCN2016 年版临床指南明确指出，肿瘤 EGFR 突变的前提下，推荐吉非替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Crizotinib</style><br/>
可用于治疗 ALK 阳性的局部进展或晚期非小细胞肺癌。NCCN2016 年版临床指南明确指出，肿瘤 ALK 重排的前提下，推荐克唑替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Afatinib</style><br/>
可用于 EGFR 突变阳性的非小细胞肺癌治疗。NCCN2016 年版临床指南明确指出，肿瘤 EGFR 突变的前提下，推荐阿 法替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Bevacizumab</style><br/>
可用于治疗转移性非小细胞肺癌。NCCN2016 年版临床指南明确指出，贝伐单抗结合卡铂和紫杉醇作为 (PS0-1) 非小细胞肺癌的一线治疗方案。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Alectinib</style><br/>
可用于治疗非小细胞肺癌进展或不能耐受克唑替尼。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ceritinib</style><br/>
可用于治疗转移性 ALK- 阳性非小细胞肺癌，且对克唑替尼耐药者。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
可用于治疗不可切除或转移性恶性黑色素瘤，转移性鳞状非小细胞肺癌。<br/><br/>


<style font='fzltchjw' font_color='#000000' font_size='13'>药物简介：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Erlotinib</style><br/>
是一类靶向 EGFR 的小分子酪氨酸激酶抑制剂，该类药物通过阻断表皮生长因子受体（EGFR）的激酶活性而抑制其磷酸化和下游信号传导，从而起到抗肿瘤作用，抑制肿瘤细胞的增生、分化同时也能增加化疗和放疗的抗肿瘤疗效。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Gefitinib</style><br/>
是一类靶向 EGFR 的小分子酪氨酸激酶抑制剂，该类药物通过阻断表皮生长因子受体（EGFR）的激酶活性而抑制其磷酸化和下游信号传导，从而起到抗肿瘤作用，抑制肿瘤细胞的增生、分化同时也能增加化疗和放疗的抗肿瘤疗效。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Crizotinib</style><br/>
是靶向 ALK／MET 的小分子酪氨酸双激酶抑制剂，该药物以 ATP 竞争的方式，结合并抑制 ALK 激酶 ALK 融合蛋白。此外，克唑替尼还抑制 MET 激酶，阻断细胞内信号转导，从而抑制癌细胞的增殖。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Afatinib</style><br/>
是靶向 EGFR／HER2 小分子酪氨酸激酶的不可逆抑制剂，作为第二代高效双重非可逆性的酪氨酸激酶抑制剂，可同时抑制 EGFR 和 HER2 两种受体，共价结合 EGFR、HER2 的激酶区域，不可逆的抑制酪氨酸激酶的自磷酸化，导致下游信号通路的下调，抑制肿瘤细胞的增殖和生长。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Bevacizumab</style><br/>
为重组人源化单克隆抗体。通过体内、体外检测系统证实 IgG1 抗体能与人血管内皮生长因子（VEGF）结合并阻断其生物 活性。而阿瓦斯汀包含了人源抗体的结构区和可结合 VEGF 的鼠源单抗的互补决定区。因此阿瓦斯汀能与 VEGF 结合从而使 VEGF 不能与它的受体 FLT-1 和 KDR 在内皮细胞表面结合，从而抑制内皮细胞增殖和新的肿瘤血管形成。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Alectinib</style><br/>
是一种 ALK 抑制剂。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ceritinib</style><br/>
是一种 ALK 抑制剂。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
是一种 BRAF 激酶抑制剂。<br/><br/>
]]>
                </parameter>
                <table id="everyDiseaseMedicine">
                    <headers>
                        <header column="0" value="药品"/>
                        <header column="1" value="英文名称"/>
                        <header column="2" value="靶点"/>
                        <header column="3" value="获批资格"/>
                    </headers>
                    <rows>
                        <cell row="0"  column="0" value="厄洛替尼"/>
                        <cell row="1"  column="0" value="吉非替尼"/>
                        <cell row="2"  column="0" value="克唑替尼"/>
                        <cell row="3"  column="0" value="阿法替尼"/>
                        <cell row="4"  column="0" value="贝伐珠单抗"/>
                        <cell row="5"  column="0" value="阿雷替尼"/>
                        <cell row="6"  column="0" value="色瑞替尼"/>
                        <cell row="7"  column="0" value="纳武单抗"/>
                        <cell row="8"  column="0" value="Tagrisso"/>
                        <cell row="9"  column="0" value="雷莫芦单抗"/>
                        <cell row="10" column="0" value="维罗非尼"/>

                        <cell row="0"  column="1" value="Erlotinib"/>
                        <cell row="1"  column="1" value="Gefitinib"/>
                        <cell row="2"  column="1" value="Crizotinib"/>
                        <cell row="3"  column="1" value="Afatinib"/>
                        <cell row="4"  column="1" value="Bevacizumab"/>
                        <cell row="5"  column="1" value="Alectinib"/>
                        <cell row="6"  column="1" value="Ceritinib"/>
                        <cell row="7"  column="1" value="Nivolumab"/>
                        <cell row="8"  column="1" value="Osimertinib"/>
                        <cell row="9"  column="1" value="Ramucirumab"/>
                        <cell row="10" column="1" value="Vemurafenib"/>

                        <cell row="0"  column="2" value="EGFR"/>
                        <cell row="1"  column="2" value="EGFR"/>
                        <cell row="2"  column="2" value="ALK / ROS1 / MET"/>
                        <cell row="3"  column="2" value="EGFR / HER2 / ERBB4"/>
                        <cell row="4"  column="2" value="VEGF / KDR"/>
                        <cell row="5"  column="2" value="ALK"/>
                        <cell row="6"  column="2" value="ALK / IGF1R"/>
                        <cell row="7"  column="2" value="PD-1"/>
                        <cell row="8"  column="2" value="EGFR"/>
                        <cell row="9"  column="2" value="VEGFR-2"/>
                        <cell row="10" column="2" value="BRAF"/>

                        <cell row="0"  column="3" value="FDA / CFDA"/>
                        <cell row="1"  column="3" value="FDA / CFDA"/>
                        <cell row="2"  column="3" value="FDA / CFDA"/>
                        <cell row="3"  column="3" value="FDA / CFDA"/>
                        <cell row="4"  column="3" value="FDA / CFDA"/>
                        <cell row="5"  column="3" value="FDA"/>
                        <cell row="6"  column="3" value="FDA"/>
                        <cell row="7"  column="3" value="FDA"/>
                        <cell row="8"  column="3" value="FDA"/>
                        <cell row="9"  column="3" value="FDA"/>
                        <cell row="10" column="3" value="FDA"/>
                    </rows>
                </table>
            </group>
            <group id="1" order="1">
                <parameter id="everyDiseaseName" value="2、肝癌"/>
                <parameter id="adaptionDiseaseMedicineInfo" value="">
                    <![CDATA[
<style font='fzltchjw' font_color='#000000' font_size='13'>获批适应症：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Sorafenib</style><br/>
可用于治疗肝细胞癌。NCCN2016 年版临床指南明确指出，建议索拉菲尼用于治疗局限或转移性肝癌。<br/><br/>


<style font='fzltchjw' font_color='#000000' font_size='13'>药物简介：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
是一种针对丝氨酸／苏氨酸和酪氨酸激酶受体的多激酶抑制剂，抑制肿瘤细胞的生长和增殖，促进细胞凋亡。<br/><br/>
]]>
                </parameter>
                <table id="everyDiseaseMedicine">
                    <headers>
                        <header column="0" value="药品"/>
                        <header column="1" value="英文名称"/>
                        <header column="2" value="靶点"/>
                        <header column="3" value="获批资格"/>
                    </headers>
                    <rows>
                        <cell row="0"  column="0" value="索拉非尼"/>

                        <cell row="0"  column="1" value="Sorafenib"/>

                        <cell row="0"  column="2" value="BRAF／KIT／KDR／PDGFRA"/>

                        <cell row="0"  column="3" value="FDA／CFDA"/>
                    </rows>
                </table>
            </group>
            <group id="2" order="2">
                <parameter id="everyDiseaseName" value="3、Fei癌"/>
                <parameter id="adaptionDiseaseMedicineInfo" value="">
                    <![CDATA[
<style font='fzltchjw' font_color='#000000' font_size='13'>获批适应症：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Erlotinib</style><br/>
可用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移的非小细胞肺癌。NCCN2016 年版临床指南明确指出，肿瘤 EGFR 突变的前提下，推荐厄洛替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Gefitinib</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Alectinib</style><br/>
可用于治疗非小细胞肺癌进展或不能耐受克唑替尼。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ceritinib</style><br/>
可用于治疗转移性 ALK- 阳性非小细胞肺癌，且对克唑替尼耐药者。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Nivolumab</style><br/>
可用于治疗转移性鳞状非小细胞肺癌。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Osimertinib</style><br/>
可用于治疗 EGFR-T790M 突变阳性的非小细胞肺癌。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ramucirumab</style><br/>
可用于治疗转移性非小细胞肺癌（经铂类联合多西他赛治疗期间或治疗后疾病仍然无进展的患者）。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
可用于治疗不可切除或转移性恶性黑色素瘤，转移性鳞状非小细胞肺癌。<br/><br/>


<style font='fzltchjw' font_color='#000000' font_size='13'>药物简介：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Erlotinib</style><br/>
是一类靶向 EGFR 的小分子酪氨酸激酶抑制剂，该类药物通过阻断表皮生长因子受体（EGFR）的激酶活性而抑制其磷酸化和下游信号传导，从而起到抗肿瘤作用，抑制肿瘤细胞的增生、分化同时也能增加化疗和放疗的抗肿瘤疗效。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Alectinib</style><br/>
是一种 ALK 抑制剂。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ceritinib</style><br/>
是一种 ALK 抑制剂。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Nivolumab</style><br/>
是一种人类的 IgG4 和抗 PD-1 单克隆抗体。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Osimertinib</style><br/>
是第三代表皮生长因子（EGFR）酪氨酸激酶抑制剂药物（TKI)。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ramucirumab</style><br/>
是实体肿瘤的治疗开发的完全人单克隆抗体（IgG1)。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
是一种 BRAF 激酶抑制剂。<br/><br/>
]]>
                </parameter>
                <table id="everyDiseaseMedicine">
                    <headers>
                        <header column="0" value="药品"/>
                        <header column="1" value="英文名称"/>
                        <header column="2" value="靶点"/>
                        <header column="3" value="获批资格"/>
                    </headers>
                    <rows>
                        <cell row="0"  column="0" value="厄洛替尼"/>
                        <cell row="1"  column="0" value="吉非替尼"/>
                        <cell row="2"  column="0" value="克唑替尼"/>
                        <cell row="3"  column="0" value="阿法替尼"/>
                        <cell row="4"  column="0" value="贝伐珠单抗"/>
                        <cell row="5"  column="0" value="阿雷替尼"/>

                        <cell row="0"  column="1" value="Erlotinib"/>
                        <cell row="1"  column="1" value="Gefitinib"/>
                        <cell row="2"  column="1" value="Crizotinib"/>
                        <cell row="3"  column="1" value="Afatinib"/>
                        <cell row="4"  column="1" value="Bevacizumab"/>
                        <cell row="5"  column="1" value="Alectinib"/>

                        <cell row="0"  column="2" value="EGFR"/>
                        <cell row="1"  column="2" value="EGFR"/>
                        <cell row="2"  column="2" value="ALK / ROS1 / MET"/>
                        <cell row="3"  column="2" value="EGFR / HER2 / ERBB4"/>
                        <cell row="4"  column="2" value="VEGF / KDR"/>
                        <cell row="5"  column="2" value="ALK"/>

                        <cell row="0"  column="3" value="FDA / CFDA"/>
                        <cell row="1"  column="3" value="FDA / CFDA"/>
                        <cell row="2"  column="3" value="FDA / CFDA"/>
                        <cell row="3"  column="3" value="FDA / CFDA"/>
                        <cell row="4"  column="3" value="FDA / CFDA"/>
                        <cell row="5"  column="3" value="FDA / CFDA"/>
                    </rows>
                </table>
            </group>
        </repeat>
        <table id="targetedDrugUsageInfo">
            <headers>
                <header column="0"  value="基因名称"/>
                <header column="1"  value="是否突变"/>
                <header column="2"  value="突变位点"/>
                <header column="3"  value="突变频率"/>
                <header column="4"  value="敏感药物"/>
                <header column="5"  value="证据级别"/>
                <header column="6"  value="不敏感药物"/>
                <header column="7"  value="证据级别"/>
                <header column="8"  value="敏感药物"/>
                <header column="9"  value="证据级别"/>
                <header column="10" value="不敏感药物"/>
                <header column="11" value="证据级别"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="KRAS"/>
                <cell row="1"  column="0" value="KIT"/>

                <cell row="0"  column="1" value="是"/>
                <cell row="1"  column="1" value="是"/>

                <cell row="0"  column="2" value="p.G12D"/>
                <cell row="1"  column="2" value="p.N512K"/>

                <cell row="0"  column="3" value="32.8%"/>
                <cell row="1"  column="3" value="44.65%"/>

                <cell row="0"  column="4" value="／"/>
                <cell row="1"  column="4" value="索拉菲尼"/>

                <cell row="0"  column="5" value="／"/>
                <cell row="1"  column="5" value="A"/>

                <cell row="0"  column="6" value="瑞格菲尼"/>
                <cell row="1"  column="6" value="／"/>

                <cell row="0"  column="7" value="A"/>
                <cell row="1"  column="7" value="／"/>

                <cell row="0"  column="8" value="曲美替尼"/>
                <cell row="1"  column="8" value="伊马替尼 舒尼替尼 帕唑帕尼"/>

                <cell row="0"  column="9" value="C"/>
                <cell row="1"  column="9" value="C"/>

                <cell row="0"  column="10" value="／"/>
                <cell row="1"  column="10" value="／"/>

                <cell row="0"  column="11" value="／"/>
                <cell row="1"  column="11" value="／"/>
            </rows>
        </table>

        <table id="targetedDrug">
            <headers>
                <header column="0" value="药物名称"/>
                <header column="1" value="英文名称"/>
                <header column="1" value="商品名"/>
                <header column="2" value="对应靶点基因"/>
                <header column="3" value="获批适应症"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="厄洛替尼"/>
                <cell row="1"  column="0" value="吉非替尼"/>
                <cell row="2"  column="0" value="克唑替尼"/>
                <cell row="3"  column="0" value="阿法替尼"/>

                <cell row="0"  column="1" value="Erlotinib"/>
                <cell row="1"  column="1" value="Gefitinib"/>
                <cell row="2"  column="1" value="Crizotinib"/>
                <cell row="3"  column="1" value="Afatinib"/>

                <cell row="0"  column="2" value="Iressa"/>
                <cell row="1"  column="2" value="Tarceva"/>
                <cell row="2"  column="2" value="Gilotrif"/>
                <cell row="3"  column="2" value="凯美纳"/>

                <cell row="0"  column="3" value="EGFR"/>
                <cell row="1"  column="3" value="EGFR"/>
                <cell row="2"  column="3" value="EGFR"/>
                <cell row="3"  column="3" value="EGFR"/>

                <cell row="0"  column="4" value="非小细胞肺癌"/>
                <cell row="1"  column="4" value="非小细胞肺癌"/>
                <cell row="2"  column="4" value="非小细胞肺癌"/>
                <cell row="3"  column="4" value="非小细胞肺癌"/>
            </rows>
        </table>
        <parameter id="targetedDrugInfo" value="">
<![CDATA[
吉非替尼是一类靶向EGFR 的小分子酪氨酸激酶抑制剂，该类药物主要通过阻断表皮生长因子受体(EGFR)的激酶活性 而抑制其磷酸化和下游信号传导，从而起到抗肿瘤作用，即抑制肿瘤细胞的增生、分化，同时也能提高化疗和放疗的抗肿 瘤疗效。适用于治疗既往接受过化学治疗或不适于化疗的局部、晚期或转移性非小细胞肺癌(NSCLC)。厄洛替尼的作 用靶点为 EGFR ，主要检测靶点为 BRAF、EGFR、KRAS 。当 EGFR 的 18/19/21 号外显子突变时，对该药物敏感， 提示临床优先使用;当 EGFR 第 20 号外显子突变、KRAS 突变时，则对吉非替尼耐药，临床不建议使用。2016 年， NCCN 指南推荐吉非替尼用于非小细胞肺癌的一线治疗。<br/><br/>
厄洛替尼是一类靶向EGFR 的小分子酪氨酸激酶抑制剂，用于治疗非小细胞肺癌(NSCLC)、胰腺癌等几种癌症。厄洛 替尼的作用靶点为 EGFR ，主要检测靶点为 BRAF、EGFR、KRAS 。当 EGFR 的 18/19/21 号外 显子突变时，对该药 物敏感，提示临床优先使用;当 EGFR 第 20 号外显子突变、KRAS 突变时，则对厄洛替尼耐药，临床不建议使用。2016 年， NCCN 指南推荐厄洛替尼用于非小细胞肺癌的一线治疗。<br/><br/>
阿法替尼可用于 EGFR 突变阳性的非小细胞肺癌治疗。NCCN 2016 年版临床指南明确指出，肿瘤 EGFR 突变的前提下， 推荐阿法替尼为非小细胞肺癌一线治疗药物。<br/><br/>
埃克替尼是一种高效特异性的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)。在对 85 种激酶的筛查中，埃克替尼 可强有力地选择性抑制 EGFR 及其 3 个突变体，但对剩余 81 种激酶均无明显的抑制作用。适用于于晚期非小细胞肺癌二 线治疗。<br/>
]]>
        </parameter>

        <table id="relativeGeneCheckedInfo">
            <headers>
                <header column="0" value="编号"/>
                <header column="2" value="靶基因"/>
                <header column="3" value="结果"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="1"/>
                <cell row="1"  column="0" value="2"/>
                <cell row="2"  column="0" value="3"/>
                <cell row="3"  column="0" value="4"/>

                <cell row="0"  column="1" value="ALK"/>
                <cell row="1"  column="1" value="BRAF"/>
                <cell row="2"  column="1" value="EGFR"/>
                <cell row="3"  column="1" value="HER2"/>

                <cell row="0"  column="2" value="无明确靶点检出"/>
                <cell row="1"  column="2" value="无明确靶点检出"/>
                <cell row="2"  column="2" value="p.L858R"/>
                <cell row="3"  column="2" value="无明确靶点检出"/>
            </rows>
        </table>

        <table id="chemotherapyGeneDetailInfo">
            <headers>
                <header column="0" value="基因"/>
                <header column="1" value="rs 编号"/>
                <header column="2" value="基因型"/>
                <header column="3" value="临床意义"/>
                <header column="4" value="证据级别"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="XRCC1"/>
                <cell row="1"  column="0" value="XRCC1"/>
                <cell row="2"  column="0" value="ERCC1"/>
                <cell row="3"  column="0" value="ERCC2"/>

                <cell row="0"  column="1" value="rs25487"/>
                <cell row="1"  column="1" value="rs1799782"/>
                <cell row="2"  column="1" value="rs11615"/>
                <cell row="3"  column="1" value="rs13181"/>

                <cell row="0"  column="2" value="GG"/>
                <cell row="1"  column="2" value="CC"/>
                <cell row="2"  column="2" value="CT"/>
                <cell row="3"  column="2" value="TT"/>

                <cell row="0"  column="3" value="对铂类药物敏感性较高"/>
                <cell row="1"  column="3" value="对铂类药物敏感性较高"/>
                <cell row="2"  column="3" value="对铂类药物敏感性较高"/>
                <cell row="3"  column="3" value="对铂类药物敏感性较高"/>

                <cell row="0"  column="4" value="2B"/>
                <cell row="1"  column="4" value="3"/>
                <cell row="2"  column="4" value="2B"/>
                <cell row="3"  column="4" value="3"/>
            </rows>
        </table>









        <table id="zhiBingJiYinYuZhongLiuGuanXi">
            <headers>
                <header column="0" value="癌种"/>
                <header column="1" value="基因数目"/>
                <header column="2" value="基因"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="乳腺癌"/>
                <cell row="1"  column="0" value="卵巢癌"/>
                <cell row="2"  column="0" value="结直肠癌"/>
                <cell row="3"  column="0" value="胃癌"/>
                <cell row="4"  column="0" value="肾癌"/>
                <cell row="5"  column="0" value="前列腺癌"/>
                <cell row="6"  column="0" value="胰腺癌"/>
                <cell row="7"  column="0" value="子宫内膜癌"/>
                <cell row="8"  column="0" value="甲状腺癌"/>
                <cell row="9"  column="0" value="甲状旁腺癌"/>
                <cell row="10" column="0" value="肺癌"/>
                <cell row="11" column="0" value="肝癌"/>
                <cell row="12" column="0" value="食管癌"/>
                <cell row="13" column="0" value="膀胱癌"/>
                <cell row="14" column="0" value="胶质瘤"/>
                <cell row="15" column="0" value="淋巴瘤"/>

                <cell row="0"  column="1" value="21"/>
                <cell row="1"  column="1" value="23"/>
                <cell row="2"  column="1" value="18"/>
                <cell row="3"  column="1" value="9"/>
                <cell row="4"  column="1" value="18"/>
                <cell row="5"  column="1" value="10"/>
                <cell row="6"  column="1" value="15"/>
                <cell row="7"  column="1" value="23"/>
                <cell row="8"  column="1" value="2"/>
                <cell row="9"  column="1" value="2"/>
                <cell row="10" column="1" value="5"/>
                <cell row="11" column="1" value="4"/>
                <cell row="12" column="1" value="4"/>
                <cell row="13" column="1" value="4"/>
                <cell row="14" column="1" value="4"/>
                <cell row="15" column="1" value="4"/>

                <cell row="0"  column="2" value="BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1,MRE11A, MSH2, MSH6, MUTYH, NBN, PMS1, PMS2, RAD50, RAD51C"/>
                <cell row="1"  column="2" value="ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53"/>
                <cell row="2"  column="2" value="APC, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, MET, PTEN, SMAD4, STK11, TP53, AXIN2, MLH3, BUB1"/>
                <cell row="3"  column="2" value="CDH1, TP53, MET, MLH1, MSH2, MSH6, PMS2, EPCAM, APC"/>
                <cell row="4"  column="2" value="EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL"/>
                <cell row="5"  column="2" value="BRCA2, BRCA1, CHEK2, NBN, HOXB13, ELAC2, HSD17B3, HSD3B2,  RNASEL, SRD5A2"/>
                <cell row="6"  column="2" value="APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53, PRSS1, SPINK1"/>
                <cell row="7"  column="2" value="ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53"/>
                <cell row="8"  column="2" value="RET,NTRK1"/>
                <cell row="9"  column="2" value="MEN1, CDC73"/>
                <cell row="10" column="2" value="EGFR, PIK3CA, KRAS, BRAF, TP53"/>
                <cell row="11" column="2" value="TP53, IQGAP1, IQGAP2, CTNNB1"/>
                <cell row="12" column="2" value="RHBDF2, ADH1B, ALDH2, CYP2E1"/>
                <cell row="13" column="2" value="KRAS, RB1, FGFR3, HRAS"/>
                <cell row="14" column="2" value="P53, IDH1, IDH2, PTEN"/>
                <cell row="15" column="2" value="KLHDC8B, ATM, MYC, PRF1"/>
            </rows>
        </table>



















        <parameter id="gaiShuZhiBingJiYinJianShu" value="">
            <![CDATA[检出致病突变<br/>根据 NCBI GeneReviews <style font="simsun">®</style>, 该杂合突变者的直结肠癌风险轻微增加。<br/>请向医生或遗传咨询师咨询。<br/>]]>
        </parameter>
        <parameter id="gaiShuZhiBingJiYinJianChu" value="">
            <![CDATA[基因名词：<style italic="true">MUTYH</style> <br/> 该基因突变的可致疾病：直结肠癌 家族性腺瘤性息肉病<br/> 基因名词：<style italic="true">FAT3</style> <br/>该基因突变的可致疾病：直结肠癌 遗传性非息肉病<br/>]]>
        </parameter>
        <parameter id="gaiShuJiBingGeShu" value="15"/>
        <parameter id="gaiShuFengXianYuFangJianYi" value="">
<![CDATA[
<style font_size="12">根据肿瘤致病基因和风险基因的检测结果，您有结直肠癌的致病基因检出阳性</style><br/>
<style font_size="12">风险基因评分均 &lt;1.5</style><br/>
<style font_size="12">您的主要肿瘤风险为：</style>
<style font="fzlthjw" font_size="12" font_color="#738c34" bold="true">结直肠癌。</style> <br/>
<style font_size="12">请参考如下建议：</style><br/>
(参见结直肠癌的健康管理措施)<br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">注意饮食</style><br/>
少吃脂肪，多吃富含膳食纤维的饮食。（剑桥大学的研究表明，高纤维饮食能有效减低患上致命癌症的危险几率达 40%，特别是结肠癌及直肠癌。）<br/>
· 膳食纤维主要来自天然的蔬菜、水果、谷类及豆类。蔬菜中的十字花科蔬菜（包括花椰菜、芥菜、白菜等）。<br/>
· 黄色和绿色蔬果，以及洋葱、苹果皮等食物中，含有丰富类黄酮素，多吃也有助于预防癌症。<br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">戒烟</style><br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">坚持规律锻炼</style><br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">定期筛查</style><br/>
美国癌症协会建议，从 50 岁开始，所有人都应该选择以下 5 种筛查方案中的一种执行，如果筛查结果为阳性，则需要做结肠镜检查。<br/>
· 每年进行粪便潜血试验（FOBT） 或者是粪便免疫化学试验（FIT）;<br/>
· 每五年乙状结肠镜检查，时间灵活;<br/>
· 每年（FOBT）或（FIT），加上每五年一次时间灵活的乙状结肠镜检查; · 每五年结肠双对比造影;<br/>
· 每十年结肠镜检查。<br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">高危人群</style><br/>
有炎症性肠道疾病或有结肠癌家族史的人群应该尽早就医，遵医嘱进行相关检查并随诊。<br/><br/>
<style font_size="11" font_color="#738c34" bold="true">经幸福基石的特约医生对您进行包括个人健康状况、家族史等全面评估后，会给出更具体建议，请遵照医生咨询后的建议。</style>
]]>
        </parameter>
        <table id="gaiShuZhiBingJiYinLieBiao">
            <headers>
                <header column="0" value="基因"/>
                <header column="1" value="突变位置"/>
                <header column="2" value="类型"/>
                <header column="3" value="致病性证据 *"/>
                <header column="4" value="人群频率 **"/>
            </headers>
            <rows>
                <cell row="0" column="0" value="MUTYH"/>
                <cell row="0" column="1" value="NM_001128425.1:c.934-2A>G"/>
                <cell row="0" column="2" value="杂合，可变剪切位点突变 splice acceptor variant"/>
                <cell row="0" column="3" value="Likely pathogenic（2 例）; Probably pathogencic（1 例）"/>
                <cell row="0" column="4" value="1%"/>

                <cell row="1" column="0" value="FAT3"/>
                <cell row="1" column="1" value="NM_001008781:exon9:c.A8263G:p.I2755V"/>
                <cell row="1" column="2" value="纯和，非同义突变"/>
                <cell row="1" column="3" value="无"/>
                <cell row="1" column="4" value="14%"/>
            </rows>
        </table>
        <table id="gaiShuJiYinFengXianPingFen">
            <headers>
                <header column="0" value="疾病"/>
                <header column="1" value="您的结果"/>
                <header column="2" value="相对风险评分"/>
                <header column="3" value="详解页码"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="乳腺癌"/>
                <cell row="1"  column="0" value="结直肠癌"/>
                <cell row="2"  column="0" value="甲状腺癌"/>
                <cell row="3"  column="0" value="子宫颈癌"/>

                <cell row="0"  column="1" value="4.76"/>
                <cell row="1"  column="1" value="4.41"/>
                <cell row="2"  column="1" value="2.19"/>
                <cell row="3"  column="1" value="1.14"/>

                <cell row="0"  column="2" value="1.46"/>
                <cell row="1"  column="2" value="1.41"/>
                <cell row="2"  column="2" value="1.19"/>
                <cell row="3"  column="2" value="1.14"/>

                <cell row="0"  column="3" value="4 1 0"/>
                <cell row="1"  column="3" value="4 2 0"/>
                <cell row="2"  column="3" value="4 3 0"/>
                <cell row="3"  column="3" value="4 4 0"/>
            </rows>
        </table>












    </data>
</pdf>